Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948021 | 0.88 | KMT2A (0.38) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL31749075 | 0.88 | KMT2A (0.38) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL30930126 | 0.86 | LMNA (0.41) | KMT2ALMNAALDH1A1HTTKDM4E | |
| SCHEMBL29382010 | 0.86 | LMNA (0.41) | KMT2ALMNAALDH1A1HTTKDM4E | |
| Trifluoromethanesulfonic Acid SCHEMBL3629145 | 0.84 | KCNH2 (0.44) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL15992996 | 0.81 | KCNH2 (0.39) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL29670916 | 0.81 | KCNH2 (0.39) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL28633185 | 0.81 | GGPS1 (0.39) | PABPC1KMT2AATMLMNAGGPS1 | |
| SCHEMBL933109 | 0.80 | KMT2A (0.32) | KMT2A | |
| SCHEMBL294294 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031875-A1 | Optically active ionic liquid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-10-18 | — | — | US | claimed |
| WO-2024223586-A1 | DEVICE, METHOD AND COMPUTER PROGRAM FOR PROCESSING OF A SURFACE OF A SUBSTRATE | CARL ZEISS SMT GMBH (DE) | 2024-10-31 | — | — | WO | disclosed |
| US-20010031875-A1 | Optically active ionic liquid | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031875-A1 | Optically active ionic liquid | IK, INF2, ICMT | PABPC1 3687/4885KMT2A 2308/4885ATM 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.